Jin J Choi

US Patent:

8410119, Apr 2, 2013

Filed:

Sep 25, 2009

Appl. No.:

12/567221

Inventors:

Robert M. Jones - San Diego CA, US
Graeme Semple - San Diego CA, US
Yifeng Xiong - San Diego CA, US
Young-Jun Shin - San Diego CA, US
Albert S. Ren - San Diego CA, US
Imelda Calderon - San Diego CA, US
Beatriz Fioravanti - Tucson AZ, US
Jin Sun Choi - San Diego CA, US
Carleton R. Sage - Encinitas CA, US

Assignee:

Arena Pharmaceuticals, Inc. - San Diego CA

International Classification:

A61K 31/519
C07D 487/00

US Classification:

5142621, 544262

Abstract:

The present invention relates to certain fused aryl and heteroaryl derivatives of Formula (I) that are modulators of metabolism.

US Patent:

20060217379, Sep 28, 2006

Filed:

Jan 14, 2004

Appl. No.:

10/541657

Inventors:

Robert Jones - San Diego CA, US
Graeme Semple - San Diego CA, US
Beatriz Fioravanti - Tucson AZ, US
Guilherme Pereira - San Diego CA, US
Imelda Calderon - San Diego CA, US
Jane Uv - Monrovia CA, US
Kameshwari Duvvuri - Lexington KY, US
Jin Choi - San Diego CA, US
Yifeng Xiong - San Diego CA, US
Vibha Dave - San Diego CA, US
Mihai Azimioara - La Jolla CA, US

International Classification:

A61K 31/5377
A61K 31/506
A61K 31/454
C07D 413/14
C07D 403/14

US Classification:

514235500, 514256000, 514326000, 544331000, 546210000, 544122000

Abstract:

The present invention relates to certain 1,2,3-trisubstituted aryl and heteroaryl derivatives of Fomula (Ia) that are modulators of metabolism. Accordingly, compounds of the present invention are useful in the prophylaxis or treatment of metabolic disorders and complications thereof, such as, diabetes and obesity.

US Patent:

20070072844, Mar 29, 2007

Filed:

Nov 20, 2006

Appl. No.:

11/602162

Inventors:

Robert Jones - San Diego CA, US
Graeme Semple - San Diego CA, US
Yifeng Xiong - San Diego CA, US
Young-Jun Shin - San Diego CA, US
Albert Ren - San Diego CA, US
Imelda Calderon - San Diego CA, US
Beatriz Fioravanti - Tuscon AZ, US
Jin Choi - San Diego CA, US
Carleton Sage - Cardiff-by-the-Sea CA, US

Assignee:

Arena Pharmaceuticals, Inc. - San Diego CA

International Classification:

A61K 31/551
A61K 31/519
C07D 487/02

US Classification:

514218000, 514262100, 544262000, 514252160, 540575000

Abstract:

The present invention relates to certain fused aryl and heteroaryl derivatives of Formula (I) that are modulators of metabolism. Accordingly, compounds of the present invention are useful in the prophylaxis or treatment of metabolic disorders and complications thereof, such as, diabetes and obesity.

US Patent:

20070207994, Sep 6, 2007

Filed:

Nov 20, 2006

Appl. No.:

11/602164

Inventors:

Bradley Teegarden - San Diego CA, US
Yifeng Xiong - San Diego CA, US
Honnappa Jayakumar - San Diego CA, US
Peter Dosa - San Diego CA, US
Konrad Feichtinger - San Diego CA, US
Martin Casper - San Diego CA, US
Juerg Lehmann - San Diego CA, US
Robert Jones - San Diego CA, US
David Unett - San Diego CA, US
Jin Karoline Choi - San Diego CA, US

International Classification:

A61K 31/553
A61K 31/55
A61K 31/541
A61K 31/5377
A61K 31/496
A61K 31/454
A61K 31/416
A61K 31/4152
C07D 417/02
C07D 413/02
C07D 403/02

US Classification:

514210200, 514227500, 514211150, 514235500, 514326000, 514341000, 514406000, 514407000, 514254050, 514217100, 540544000, 540603000, 544060000, 544140000, 544371000, 546210000, 546275100, 548364100, 548366100, 548371100

Abstract:

The present invention relates to certain 3-phenyl-pyrazole derivatives of Formula (Ia) and pharmaceutical compositions thereof that modulate the activity of the 5-HTserotonin receptor. Compounds and pharmaceutical compositions thereof are directed to methods useful in the treatment of platelet aggreagation, coronary artery disease, myocardial infarction, transient ischemic attack, angina, stroke, atrial fibrillation, reducing the risk of blood clot formation, asthma or symptoms thereof, agitation or a symptom, behavioral disorders, drug induced psychosis, excitative psychosis, Gilles de la Tourette's syndrome, manic disorder, organic or NOS psychosis, psychotic disorder, psychosis, acute schizophrenia, chronic schizophrenia, NOS schizophrenia and related disorders, and sleep disorders, sleep disorders, diabetic-related disorders, progressive multifocal leukoencephalopathy and the like. The present invention also relates to the methods for the treatment of 5-HTserotonin receptor mediated disorders in combination with other pharmaceutical agents administered separately or together.

US Patent:

20070244086, Oct 18, 2007

Filed:

Nov 17, 2005

Appl. No.:

11/597306

Inventors:

Bradley Teegarden - San Diego CA, US
Yifeng Xiong - San Diego CA, US
Honnappa Jayakumar - San Diego CA, US
Peter Dosa - San Diego CA, US
Konrad Feichtinger - San Diego CA, US
Martin Casper - San Diego CA, US
Juerg Lehmann - San Diego CA, US
Robert Jones - San Diego CA, US
David Unett - San Diego CA, US
Jin Karoline Choi - San Diego CA, US

International Classification:

A61K 31/4155
A61K 31/397
A61K 31/4178
A61K 31/454
A61K 31/496
A61K 31/5355
A61K 31/541
A61K 31/553
A61P 29/00
C07D 231/12
C07D 231/16
C07D 401/12
C07D 403/12
C07D 405/12
C07D 409/12
C07D 413/12
C07D 417/12
C07D 487/08

US Classification:

514210200, 514211150, 514227800, 514236500, 514254040, 514326000, 514385000, 514406000, 540544000, 544140000, 544371000, 544060000, 546211000, 548314700, 548356100, 548364100, 548518000, 548952000

Abstract:

The present invention relates to certain 3-phenyl-pyrazole derivatives of Formula (Ia) and pharmaceutical compositions thereof that modulate the activity of the 5-HTserotonin receptor. Compounds and pharmaceutical compositions thereof are directed to methods useful in the treatment of platelet aggregation, coronary artery disease, myocardial infarction, transient ischemic attack, angina, stroke, atrial fibrillation, reducing the risk of blood clot formation, asthma or symptoms thereof, agitation or a symptom, behavioral disorders, drug induced psychosis, excitative psychosis, Gilles de la Tourette's syndrome, manic disorder, organic or NOS psychosis, psychotic disorder, psychosis, acute schizophrenia, chronic schizophrenia, NOS schizophrenia and related disorders, and sleep disorders, sleep disorders, diabetic-related disorders, progressive multifocal leukoencephalopathy and the like. The present invention also relates to the methods for the treatment of 5-HTserotonin receptor mediated disorders in combination with other pharmaceutical agents administered separately or together.

Address:

8520 Costa Verde Blvd APT 3226, San Diego, CA 92122

VIN:

WAUDF78E87A032916

Make:

AUDI

Model:

A4

Year:

2007